Drug Profile
Dovitinib companion diagnostic - Allarity Therapeutics
Alternative Names: Dovitinib DRP®; Dovitinib DRP® companion diagnosticLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Oncology Venture
- Developer Allarity Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Renal cancer
- No development reported Breast cancer; Endometrial cancer; Gastrointestinal stromal tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in USA
- 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Endometrial-cancer(Diagnosis) in USA
- 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-stromal-tumours(Diagnosis) in USA